Skip to content
10-Q

Quarterly Report

CHINA PHARMA HOLDINGS, INC. CPHI

0001213900-24-097461

← back to feed
Filed
Nov 13, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 12, 2024 19.25M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $700K
Current Liabilities Q3 2024 · Sep 30, 2024 $4.76M
Current Liabilities Q3 2024 · Dec 31, 2023 $6.82M
Total Liabilities Q3 2024 · Sep 30, 2024 $6.94M
Total Liabilities Q3 2024 · Dec 31, 2023 $9.01M
Current Assets Q3 2024 · Sep 30, 2024 $3.74M
Current Assets Q3 2024 · Dec 31, 2023 $6M
Total Assets Q3 2024 · Sep 30, 2024 $13.47M
Total Assets Q3 2024 · Dec 31, 2023 $16.47M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$677.36K
Stockholders Equity Q3 2024 · Sep 30, 2023 $6.11M
Stockholders Equity Q3 2024 · Jun 30, 2023 $4.35M
Stockholders Equity Q3 2024 · Mar 31, 2023 $4.67M
Stockholders Equity Q3 2024 · Dec 31, 2022 $4.29M
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$0.29
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$0.89
Eps Basic restated Q3 2024 · Sep 30, 2023 −$0.29
Eps Basic restated Q3 2024 · Sep 30, 2023 −$0.89
Sga Expense Q3 2024 · Sep 30, 2023 $246.27K
Sga Expense Q3 2024 · Sep 30, 2023 $776.3K
Rd Expense Q3 2024 · Sep 30, 2023 $45.77K
Rd Expense Q3 2024 · Sep 30, 2023 $92.53K
Net Income Q3 2024 · Sep 30, 2023 −$777.6K
Net Income Q3 2024 · Sep 30, 2023 −$1.85M
Net Income Q3 2024 · Jun 30, 2023 −$593.03K
Net Income Q3 2024 · Mar 31, 2023 −$475.98K
Operating Income Q3 2024 · Sep 30, 2023 −$713.54K
Operating Income Q3 2024 · Sep 30, 2023 −$1.57M
Gross Profit Q3 2024 · Sep 30, 2023 −$233.19K
Gross Profit Q3 2024 · Sep 30, 2023 −$201.93K
Cost Of Revenue Q3 2024 · Sep 30, 2023 $2.04M
Cost Of Revenue Q3 2024 · Sep 30, 2023 $5.06M
Revenue Q3 2024 · Sep 30, 2023 $1.8M
Revenue Q3 2024 · Sep 30, 2023 $4.86M